Heron TherapeuticsHRTX
HRTX
About: Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
Employees: 122
0
Funds holding %
of 7,429 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
10,381% more call options, than puts
Call options by funds: $3.25M | Put options by funds: $31K
106% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 31
33% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 18
3.97% more ownership
Funds ownership: 81.91% [Q1] → 85.88% (+3.97%) [Q2]
2% more funds holding
Funds holding: 165 [Q1] → 169 (+4) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]
1% less capital invested
Capital invested by funds: $274M [Q1] → $271M (-$3.27M) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$3
117%
upside
Avg. target
$4.50
226%
upside
High target
$6
335%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Needham Serge Belanger | 117%upside $3 | Buy Maintained | 8 Aug 2025 |
HC Wainwright & Co. Brandon Folkes | 335%upside $6 | Buy Initiated | 9 Jun 2025 |
Financial journalist opinion
Based on 9 articles about HRTX published over the past 30 days
Neutral
PRNewsWire
1 week ago
Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value
CARY, N.C. , Aug. 15, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that its Board of Directors (the "Board") has adopted a Section 382 rights plan (the "Rights Plan") designed to protect the availability and significant potential value of the Company's net operating loss carryforwards ("NOLs") and other tax attributes, which may be used to offset future taxable income. The Board unanimously approved the adoption of the Rights Plan.
Neutral
Seeking Alpha
2 weeks ago
Heron Therapeutics, Inc. (HRTX) Q2 2025 Earnings Call Transcript
Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q2 2025 Earnings Conference Call August 8, 2025 8:30 AM ET Company Participants Craig Alexander Collard - CEO & Director Ira Duarte - Executive VP & CFO Mark E. Hensley - Executive VP & COO Melissa Jarel - Executive Director of Legal Conference Call Participants Brandon Richard Folkes - H.C.
Positive
Zacks Investment Research
2 weeks ago
Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Negative
Zacks Investment Research
2 weeks ago
Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates
Heron Therapeutics (HRTX) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.06 per share a year ago.
Positive
The Motley Fool
2 weeks ago
Heron (HRTX) Q2 Acute Care Jumps 56%
Heron (HRTX) Q2 Acute Care Jumps 56%
Neutral
PRNewsWire
2 weeks ago
Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile
CARY, N.C. , Aug. 8, 2025 Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the completion of a comprehensive capital restructuring designed to enhance the Company's financial flexibility, reduce total debt, and support long-term growth. The multi-faceted refinancing transaction consisted of the following key components: A new senior credit facility with Hercules Capital, Inc. (NYSE: HTGC), due in 2030, which provides $110.0 million in committed capital at closing and an additional $40.0 million in two $20.0 million tranches available upon achievement of certain milestones, to be drawn at the Company's discretion; An exchange agreement with the existing holder of Heron's 1.5% senior convertible notes due 2026 to retire outstanding principal, including repayment of approximately $125.0 million in cash and conversion of $25.0 million into common stock; Issuance and sale of $35.0 million of new 5.0% senior convertible notes due 2031; and A private placement with select investors for $27.7 million in gross proceeds through the issuance of common and preferred equity.
Neutral
PRNewsWire
2 weeks ago
Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress
Generated Q2 2025 Net Revenue of $37.2 million and year-to-date revenue of $76.1 million; reaffirmed 2025 Net Revenue Guidance of $153 million - $163 million Delivered record year-to-date 2025 Adjusted EBITDA of $7.9 million, raised full-year 2025 Adjusted EBITDA Guidance from $4.0 million - $12.0 million to $9.0 million - $13.0 million ZYNRELEF ® unit demand grew 6.3% in Q2 2025 as compared to Q1 2025, with revenue impacted by a temporary wholesaler adjustment from the 400mg VAN transition; momentum building ahead of expanded commercial initiatives and dedicated sales team in Q3 2025 APONVIE ® unit demand grew 19% in Q2 2025 as compared to Q1 2025, supported by increased adoption in hospital systems and momentum building ahead of the newly launched dedicated sales team in Q3 2025 Completed comprehensive capital restructuring, reducing total debt from $175 million to $145 million and extending debt maturities to at least 2030, enhancing financial flexibility to support growth CARY, N.C. , Aug. 8, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three and six months ended June 30, 2025 and recent corporate updates.
Neutral
PRNewsWire
2 weeks ago
Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025
CARY, N.C. , Aug. 8, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that it has rescheduled its release of second quarter 2025 financial results and subsequent conference call. The Company will now host its conference call and live webcast on Friday, August 8, 2025, at 8:30 a.m.
Neutral
PRNewsWire
4 weeks ago
Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025
CARY, N.C. , July 28, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, August 11, 2025, at 4:30 p.m. ET to report second quarter 2025 financial results and discuss recent business highlights.
Positive
Zacks Investment Research
1 month ago
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Charts implemented using Lightweight Charts™